Multiple lines of evidence indicate that immunotherapies, including checkpoint inhibitors such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), are efficient strategies to shoot tumor cells.
However, only a few percent of patients with specific cancer types are able to get long-lasting responses to immunotherapies. As an integrin-associated protein CD47 is expressed in a wide range on cell surfaces and is responsible for immunity from macrophage-mediated macrophage phagocytosis by interfering with phagocyte-expressed signals.
A higher expression of CD47 has been observed in various hematological and solid malignancies when compared to normal cells. You can know more about the Boster Bio Anti-CD47 Antibody Picoband™ catalog online.
Image Source: Google
The axis CD47-SIRPa is targeted to promote macrophages' migration into tumors and results in TAMs changing their functional phenotype from a tumor-promoting M2-like to an M1-like tumoricidal phenotype, permitting TAMs to attack the tumor. In mouse models of xenografts, stopping CD47 caused an increase in presence of TAMs with an M1-like phenotype.
2C8, a unique monoclonal CD47 antibody that exhibits high specificity and affinity CD47 protein. It stimulates M0, M1, and M2 macrophages to phagocytose more efficiently than existing anti-CD47 antibodies such as B6H12.2
In vitro which inhibits the growth of tumors in vivo increasing the survival of mice. In addition, the 2C8 antibody can activate macrophages and remove cancerous cells, which could be an attractive option for treating cancer.